UK Medicine Shortages: The Complete Guide

What Are Medicine Shortages?

A medicine shortage occurs when the demand for a medication exceeds available supply, resulting in patients being unable to obtain their prescribed treatment from their pharmacy. Shortages range from brief, localised stock-outs lasting a few days to prolonged national unavailability lasting months or even years.

The UK defines a shortage formally when the DHSC (Department of Health and Social Care) is notified by a manufacturer of a supply disruption through a Medicine Supply Notification (MSN), or when pharmacy reports indicate widespread unavailability. The Specialist Pharmacy Service (SPS) publishes these notifications, which MediWatch monitors and tracks in real time.

Not all shortages are equal. A temporary stock-out of a widely available painkiller is very different from a months-long shortage of a critical epilepsy drug where switching carries real clinical risk. Understanding the difference — and knowing what mechanisms exist to help you — is what this guide is about.

How the UK Medicine Supply Chain Works

To understand why shortages happen, you first need to understand how medicines get from factory to pharmacy shelf. The UK medicine supply chain has several key stages:

1. Active Pharmaceutical Ingredient (API) Manufacturing

The raw chemical compounds that form the basis of medicines — called APIs — are predominantly manufactured in China and India. Industry estimates suggest these two countries produce 60–80% of the world's APIs. This geographic concentration creates significant vulnerability: a factory fire in Hyderabad, a regulatory shutdown in Zhejiang, or an export restriction from either government can ripple through the global supply chain within weeks.

2. Finished Product Manufacturing

APIs are then turned into tablets, capsules, liquids, creams, and other formulations by pharmaceutical manufacturers. Some of this happens in the UK (companies like GSK and AstraZeneca maintain UK facilities), but much is done in Europe, the US, and increasingly in India. Manufacturing is heavily regulated by the MHRA (Medicines and Healthcare products Regulatory Agency) — any change to the manufacturing process, even a change of supplier for a single excipient, can require regulatory re-approval that takes months.

3. Wholesalers

The UK has three major full-line pharmaceutical wholesalers: Alliance Healthcare (now part of Cencora), AAH (McKesson), and Phoenix Healthcare. These companies buy from manufacturers and supply the majority of community pharmacies. They typically hold 2–4 weeks of stock for most medicines. When a manufacturer signals a supply disruption, wholesaler stock depletes rapidly — often before pharmacies even hear about the problem.

4. Parallel Importing

Parallel importers buy medicines in EU/EEA countries where prices are lower (Greece, Spain, Eastern Europe) and sell them in the UK at a profit. This is legal and accounts for a meaningful share of UK supply for some medicines. However, post-Brexit, parallel import from the EU to the UK has become more complex. The UK can no longer freely access EU-licensed products without separate MHRA approval, and parallel import volumes have declined for many products.

5. Community Pharmacies and Hospital Pharmacies

The approximately 14,000 community pharmacies in England, Scotland, Wales, and Northern Ireland are where patients collect their prescriptions. Hospital pharmacies operate separately and often have their own procurement and stockholding arrangements. Dispensing GPs in rural areas also supply medicines directly.

6. The DHSC's Role

The DHSC's Medicine Supply Team sits at the centre. They receive early warning notifications from manufacturers, monitor wholesaler stock levels, issue Serious Shortage Protocols when needed, and can intervene to prevent parallel export (stopping medicines being shipped out of the UK during a domestic shortage). They also set reimbursement prices through the Drug Tariff, which directly influences whether supplying a medicine to the UK market is commercially viable.

Types of Medicine Shortages

Not all shortages have the same cause. Understanding the type helps you predict how long it might last and what alternatives might be available:

Manufacturing Disruption

The most common type. A factory shutdown — whether for planned maintenance, equipment failure, contamination, or regulatory action by the MHRA or other authorities — halts production. These shortages typically last 3–12 months depending on the complexity of restarting production. Example: Crescent Pharma's metformin supply issues in 2024 due to production line upgrades.

Raw Material / API Shortage

When the underlying chemical ingredient is in short supply globally, all manufacturers of that medicine are affected simultaneously. These are often the most severe shortages because there is no simple "switch to another supplier" option. Example: the global shortage of the active ingredient for certain ADHD stimulant medications that began in late 2023.

Regulatory Shortage

Caused by regulatory action — a product recall due to contamination, a change in licensed indication, or the need for re-registration post-Brexit. The valsartan recall in 2018–2019 (due to NDMA contamination) is a prime example: multiple generic manufacturers were shut down simultaneously, causing a prolonged shortage of a widely prescribed blood pressure medication.

Commercial Discontinuation

A manufacturer decides it is no longer commercially viable to produce a medicine for the UK market. This can happen when the DHSC-set reimbursement price is too low, the market is too small, or the company is restructuring. Patients on discontinued products need to be switched to alternatives — which requires GP involvement and clinical oversight. These shortages are permanent unless another manufacturer steps in.

Demand Surge

A sudden increase in demand that outstrips existing supply. This can be triggered by new NICE guidelines recommending a treatment more broadly, a pandemic (as seen with COVID-19 in 2020), media coverage creating anxiety-driven demand, or a genuine increase in diagnoses (as with ADHD). The Ozempic/semaglutide shortage from 2023 onwards was partly driven by off-label demand for weight loss diverting supply from diabetic patients.

Parallel Export

When medicines are bought in the UK and exported to other countries where they fetch a higher price. The DHSC can issue export restrictions to prevent this, but enforcement is imperfect. This has been a contributing factor in shortages of several diabetes and hormone products.

The Scale of the Problem: Live Data

These figures are drawn directly from MediWatch's database, which aggregates official DHSC Medicine Supply Notifications and NHS England Serious Shortage Protocols. The numbers fluctuate as new shortages emerge and existing ones resolve — you can see live status on our shortage tracker.

Medicine shortages have been increasing globally over the past decade. The European Medicines Agency reported a 60% increase in shortage notifications between 2019 and 2023. The UK is no exception — the combination of Brexit, COVID-19, and structural supply chain issues has made shortages more frequent and more severe. The Pharmaceutical Services Negotiating Committee (PSNC) estimates that managing shortages costs community pharmacies approximately £37 million per year in additional staff time alone.

The Regulatory Framework

The UK has specific regulatory mechanisms to manage medicine shortages. Understanding these helps you know what support is available:

Serious Shortage Protocols (SSPs)

SSPs are the primary tool. Issued by the DHSC under the Human Medicines Regulations 2012, an SSP allows community pharmacists to supply an alternative medicine without going back to the prescriber for a new prescription. For example, if an SSP is active for a specific brand of blood pressure tablet, the pharmacist can dispense a different brand, a different strength (adjusting the dose), or a different formulation (switching from tablets to capsules) as specified in the protocol.

Important for patients: When an SSP is used, you should never pay more than the standard NHS prescription charge (currently £9.90 in England). The pharmacist should explain that they are using an SSP and what they are dispensing instead.

DHSC Medicine Supply Notifications (MSNs)

These are formal notices published through the Specialist Pharmacy Service (SPS) when a manufacturer reports a supply disruption. MSNs include information about the affected product, expected duration, and any recommended alternatives. They are the primary source of data that MediWatch tracks.

Community Pharmacy Reimbursement

The Drug Tariff sets the prices at which the NHS reimburses pharmacies for medicines. When a shortage drives up the open-market price of a medicine above the Drug Tariff reimbursement price, pharmacies lose money on every pack dispensed. The DHSC can issue price concessions (also called concessionary prices) to bridge this gap, but these are often slow to be published and may not cover the full cost increase. This commercial pressure means some pharmacies stop actively trying to source shorted medicines — they literally can't afford to dispense them.

Export Restrictions

Under the Human Medicines (Amendment) Regulations, the DHSC can restrict the parallel export of specific medicines to protect domestic supply. These restrictions prevent UK-based wholesalers from selling stock abroad when there is a domestic shortage.

Emergency Supply by Pharmacists

Under Regulation 225 of the Human Medicines Regulations 2012, pharmacists can make an emergency supply of a prescription-only medicine at the request of a patient without a prescription, provided there is an immediate clinical need and it is impractical to obtain a prescription. The supply is limited to up to 30 days for most medicines (5 days for controlled drugs in Schedule 2–5). The pharmacist must interview the patient and be satisfied that the treatment has been prescribed before.

Timeline: Major UK Shortages 2022–2026

The UK has experienced a succession of major shortage crises in recent years:

Most Commonly Affected Medicines

Based on MediWatch data and DHSC notifications, these therapeutic areas face the most persistent and impactful shortages:

What to Do: 5-Step Patient Action Plan

If you arrive at the pharmacy and your medicine is unavailable, here is exactly what to do, step by step:

Your Rights as a Patient

UK patients have specific rights when it comes to medicine access during shortages:

• Duty to supply: Pharmacists have a contractual obligation under their NHS Terms of Service to make reasonable efforts to source and supply your prescribed medicine. They cannot simply turn you away.
• Emergency supply entitlement: You're entitled to an emergency supply from any pharmacist if you have an immediate clinical need and it's impractical to get a new prescription. This is law, not discretion.
• SSP price protection: If a pharmacist uses a Serious Shortage Protocol to supply you with an alternative, you should never pay more than the standard NHS prescription charge (£9.90 in England, free in Scotland, Wales, and Northern Ireland).
• GP support for switching: Your GP must provide clinical support for switching to alternatives. If they refuse to engage, you can request a different GP within the practice or make a formal complaint.
• Out-of-area prescriptions: If your medicine is available in another area, you can ask your GP for a prescription that you can take to any pharmacy in England. You are not restricted to pharmacies near your GP surgery.
• Hospital outpatient dispensing: In some cases, hospital outpatient pharmacies may have stock when community pharmacies don't, particularly for specialist medicines. Ask your specialist if this is an option.
• Formal complaints: If you receive inadequate care, you can complain through the NHS complaints process or contact PALS (Patient Advice and Liaison Service) at your local NHS trust. For pharmacy complaints, you can also contact the General Pharmaceutical Council (GPhC).

What Happens Behind the Pharmacy Counter

Community pharmacists are on the front line of managing shortages, and understanding what they deal with can help you work with them more effectively.

The PSNC estimates that pharmacists spend up to 20 hours per week managing shortages — time that comes directly from patient-facing care. When a shortage hits, pharmacists must:

• Check stock across multiple wholesalers (Alliance, AAH, Phoenix) — each has its own ordering system
• Phone other pharmacies to locate stock
• Contact GP surgeries to request alternative prescriptions — this can involve long waits on hold
• Explain the situation to patients, many of whom are understandably frustrated and anxious
• Document every SSP use and every emergency supply for regulatory compliance
• Manage the commercial impact — when a medicine costs more than the Drug Tariff reimburses, the pharmacy absorbs the loss

How you can help: Be patient with your pharmacist. They are almost certainly aware of the shortage and doing their best. Provide your full details (name, DOB, medication, dose, prescriber) clearly. Ask what you can do rather than demanding solutions. A good relationship with your regular pharmacist can make a real difference — they are more likely to hold stock for patients they know and to proactively source alternatives.

Detailed guide: how pharmacies handle shortages →

The GP Perspective

GPs face their own challenges during medicine shortages:

• Clinical responsibility: Any switch to an alternative medicine requires the GP (or specialist prescriber) to assess clinical appropriateness, potential interactions, and monitoring requirements. This is not a rubber-stamp exercise — particularly for medicines like epilepsy drugs, where switching brands can affect blood levels and seizure control.
• Administrative burden: A single shortage can generate hundreds of phone calls and prescription change requests for a busy practice. GP surgeries report that managing shortages is one of the most time-consuming administrative tasks they face.
• Prescribing guidance: The British National Formulary (BNF), NICE guidance, and local formularies guide GPs on appropriate alternatives. In practice, GPs often consult with community pharmacists to identify what's actually available before prescribing an alternative.
• Communication gap: GPs are not always notified of shortages as quickly as pharmacists. Some learn about a shortage when patients start calling to report they can't fill their prescriptions. The DHSC's notification system reaches pharmacies more directly than GP surgeries.

Government Response & Oversight

The UK government manages medicine shortages through several bodies and mechanisms:

DHSC Medicine Supply Team

The primary government body responsible for monitoring and managing shortages. They receive early warning notifications from manufacturers, monitor wholesaler stock levels, issue SSPs, and coordinate with the MHRA. The team has grown significantly since Brexit, recognising the increased UK-specific supply risk.

MHRA (Medicines and Healthcare products Regulatory Agency)

The MHRA regulates all medicines sold in the UK. Post-Brexit, it operates independently from the European Medicines Agency (EMA). This means every medicine sold in the UK requires separate MHRA approval — adding time and cost for manufacturers who previously only needed a single EU-wide authorisation. The MHRA has introduced expedited assessment pathways and mutual recognition agreements to mitigate this, but the regulatory divergence remains a structural factor in supply challenges.

NHS England

NHS England issues commissioning guidance during shortages, coordinates between trusts and community services, and manages the Medicines Value Programme which aims to improve procurement efficiency and supply resilience. The Regional Medicines Optimisation Committees (RMOCs) develop guidance for managing specific shortage situations.

What's Being Done

• Strategic stockpiling: The government maintains emergency reserves of essential medicines — expanded significantly following COVID-19 and Brexit
• Domestic manufacturing investment: The UK Life Sciences Vision includes targets for increased domestic API and finished product manufacturing to reduce import dependency
• Faster regulatory pathways: The MHRA's International Recognition Framework allows it to accept regulatory decisions from trusted overseas agencies, speeding up approvals
• Digital tracking: Improved real-time monitoring systems are being developed, including automated pharmacy stock reporting and early warning analytics
• VPAS (Voluntary Pricing and Access Scheme): The current pricing agreement with pharmaceutical companies is being reformed to better balance affordability with supply security

How to Protect Yourself

• Order early: Request repeat prescriptions 7–14 days before running out, not the day before. Most GP surgeries allow 7-day advance ordering through the NHS App or Patient Access.
• Know your alternatives: Discuss backup medications with your GP before a shortage hits. If you take methylphenidate and Elvanse could work as an alternative, having that conversation in advance saves crisis-mode GP appointments later.
• Build a small buffer: It is legal and sensible to maintain a 1–2 week buffer by ordering repeats slightly before your current supply runs out. How to build a prescription buffer legally →
• Use MediWatch alerts: Free alerts give you early warning so you can act before stock runs out completely.
• Build pharmacy relationships: A pharmacist who knows you will proactively flag potential supply issues and may reserve stock when they know a shortage is developing.
• Keep records: Maintain a written or digital list of your medicines — drug name, dose, strength, brand (if brand-specific), and prescriber. This helps if you need to access emergency supplies from an unfamiliar pharmacy.
• Register with the NHS App: You can order repeat prescriptions, view your GP record, and manage your medication list all in one place — useful for communicating with any healthcare provider during a shortage.

The Future of Medicine Supply

The medicine shortage problem is unlikely to disappear, but several structural changes are underway that could improve the situation over the medium term:

• Domestic manufacturing: Government investment in UK-based pharmaceutical manufacturing is increasing. The Medicines Manufacturing Innovation Centre in Scotland and expanded capacity at UK generics manufacturers aim to reduce import dependency for essential medicines.
• AI-powered demand forecasting: Both the DHSC and private sector are developing machine learning models to predict shortages before they happen, using prescription data, manufacturing signals, and global supply chain intelligence.
• Supply chain diversification: Efforts to reduce dependence on China and India for APIs include developing alternative suppliers in Europe, North America, and Southeast Asia. The EU's Critical Medicines Act (proposed 2025) aims to incentivise European API production.
• International cooperation: Despite Brexit, the UK is pursuing mutual recognition agreements with regulatory agencies worldwide. The Access Consortium (UK, Australia, Canada, Singapore, Switzerland) enables work-sharing on medicine assessments.
• Regulatory reform: The MHRA is reviewing its processes to reduce the time and cost for manufacturers to supply the UK market, including simplified variation processes and faster generic approvals.

Frequently Asked Questions

Explore More Guides

See also